biovu Archives
Anti-nausea drug response in children
Jan. 10, 2023—Genetic variation in a metabolic enzyme was not associated with response to the anti-nausea drug odansetron in children, Vanderbilt researchers report.
Nashville Biosciences and Illumina announce sequencing agreement with Amgen
Jan. 9, 2023—Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples.
Vanderbilt University Medical Center’s BioVU reaches milestone with biological samples
Dec. 19, 2022—BioVU, Vanderbilt University Medical Center’s biobank, has reached another milestone — deep-freeze storage of more than 300,000 biological samples.
New high-tech biobank safeguards critical specimens
Aug. 25, 2022—by Bill Snyder Vanderbilt University Medical Center has opened a state-of-the-art automated biobanking system that can store as many as 10 million biospecimens, including blood and body fluids, tissue, and genetic and protein material, at temperatures down to minus 80 degrees Celsius. The “BioStore” was purchased from its manufacturer, Massachusetts-based Azenta Life Sciences, with the...
Genotype-specific blood counts
Aug. 11, 2022—Vanderbilt researchers report genotype-specific reference ranges to improve interpretation of laboratory blood results in African Americans with a common gene variant that lowers white blood cell counts.
Study shows genotype leads to discontinued, decreased medication
Jun. 29, 2022— by Jill Clendening Patients whose race is recorded as Black in their electronic health record (EHR) are more likely to have azathioprine, an immunosuppressant medication, discontinued or its dose reduced because their laboratory results show a low white blood cell count. This lab finding was not a factor of race, but instead was linked...
BMI genetics influence heart function
Jun. 16, 2022—Vanderbilt researchers have discovered that a genetic predisposition to elevated body mass index increases the risk of diastolic dysfunction — a cardiac condition that can lead to heart failure.
BioVU celebrates 15 years supporting personalized medicine
Jun. 8, 2022—BioVU is celebrating its 15th year and has enabled hundreds of studies and publications exploring the genetic underpinnings of a host of conditions including cancer, heart disease and diabetes.
Genetics and blood pressure
May. 19, 2022—Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.
A clue to an adverse drug event in children
May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.
Gene variants and transplant drug dose
May. 9, 2022—Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.
Gene network linked to Type 2 diabetes
May. 5, 2022—Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.
